Recombinant Antibodies hold great promise as biotherapeutics and as reagents for diagnostics and drug discovery.  They have proven themselves superb tools in both genomics and proteomics, promising continued growth in this research area.  All of these trends place a tremendous emphasis on the development of new approaches for faster antibody development, improved methods of selection and optimization, alternatives for production, and evaluation for novel applications. This conference will provide you with key updates on important developments in each of these areas.

Scientific Advisors
Peter Hudson, Ph.D., AviPep
Lutz Jermutus, Ph.D., MedImmune
Arne Skerra, Ph.D., Technical University of Munich

Basic Science: Understanding, Selection, Expression

Understanding Agonism Activity of Anti-Fas Antibodies
Matthieu Chodorge, Ph.D., Research Scientist, Oncology Display Technology, MedImmune

Selection of Conformational Antibodies and their use in Cell Biology
Franck Perez, Ph.D., Research Director, CNRS UMR 144, Institute Curie

Therapeutic Antibody Production in Mammalian Cells at Lab Scale: Comparison, Adaptation and Implementation of Strategies for Improvements in Quality, Time and Cost
Gerald Casperson, Ph.D., Associate Research Fellow, Biotherapeutics, Pfizer

Novel Site-Specific PEGylation of Antibody Fragments
Ji-won Choi, Ph.D., Department Head, Biology, PolyTherics Limited

Spatially Addressed Combinatorial Protein Libraries for Drug Discovery
Vaughn Smider, M.D., Ph.D., Fabrus LLC

Antibody Affinities, Polyspecificity and Single Molecule Studies

Constant Region Effects on Antibody Specificity and Affinity
Arturo Casadevall, M.D., Ph.D., Chair, Department of Microbiology & Immunology, Albert Einstein College of Medicine

Structural Basis of Affinity Maturation
Roy Mariuzza, Ph.D., C.A.R.B., University of Maryland Biotechnology Institute, UMD

High Affinity Sea Lamprey Monoclonal Antibodies
Zeev Pancer, Ph.D., Center of Marine Biotechnology, UMBI

Antibacterial Activity of Polyreactive Antibodies
Abner Notkins, Ph.D., NIDCR, NIH (Tentatively Confirmed)

The Next Stage

Minimalist Synthetic Antibodies
Sachdev Sidhu, Ph.D., Associate Professor, Molecular Genetics, University of Toronto

Case Studies

VB6-845:  An Immunotoxin Optimized for Clinical Development
Jeannick Cizeau, Ph.D., Director, Research, Viventia Biotech Inc.

Forte Bio
Speaker and Title to be Announced

Slonomics^®  – A Unique Technology for the Generation of Highly Designed Gene Libraries
Thomas Waldmann, Ph.D., Science and Technology Applications, Sloning BioTechnology

Engineering Antibody Species Cross-Reactivity
David Lowe, Ph.D., Head of Display Technology, RI & A, MedImmune

For questions or suggestions about the meeting, please contact:
Elizabeth Lamb
Cambridge Healthtech Institute
Phone: 207-493-7874
email: elamb@healthtech.com 

For sponsorship and exhibit information, contact:
Carol Dinerstein
Phone: 781-972-5471 
email: dinerstein@healthtech.com